The standardized mortality rate for pancreas malignant neoplasms in the US is forecasted to remain stable at 14.1 deaths per hundred thousand persons from 2024 to 2028. This stability follows the 2023 rate, which was also 14.1, indicating no year-on-year change. From a broader five-year perspective, this suggests a compound annual growth rate (CAGR) of 0%, emphasizing a consistent trend over time without significant fluctuations.

Future trends to watch for:

Advancements in medical research and early detection techniques that could potentially reduce mortality rates.
Healthcare policy changes and their impacts on patient access to treatment and outcomes.
Demographic shifts, such as aging population dynamics, which might influence future mortality rates.
Innovative therapeutic approaches and their adoption rates within standard care practices.